

# Rigas G Kalaitzidis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6115512/publications.pdf>

Version: 2024-02-01

39  
papers

800  
citations

516215

16  
h-index

500791

28  
g-index

39  
all docs

39  
docs citations

39  
times ranked

1203  
citing authors

#	ARTICLE	IF	CITATIONS
1	Opportunistic screening for hypertension: what does it say about the true epidemiology?. Journal of Human Hypertension, 2022, 36, 364-369.	1.0	3
2	Tadalafil in patients on antihypertensive medications: Does safety remain an issue?. Journal of Clinical Hypertension, 2022, 24, 179-181.	1.0	2
3	Chronic Pain and Its Association with Depressive Symptoms and Renal Function in Hypertensive Patients. International Journal of Environmental Research and Public Health, 2022, 19, 1899.	1.2	0
4	Overview of infections as an etiologic factor and complication in patients with vasculitides. Rheumatology International, 2022, 42, 759-770.	1.5	9
5	Hypertension is the crucial link between obstructive sleep apnea and arterial stiffness. Journal of Clinical Hypertension, 2022, 24, 398-400.	1.0	2
6	Endothelial Dysfunction in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Life, 2022, 12, 718.	1.1	10
7	Serum Uric Acid Levels and Cardiometabolic Profile in Middle-Aged, Treatment-Naïve Hypertensive Patients. High Blood Pressure and Cardiovascular Prevention, 2022, , 1.	1.0	2
8	COVID-19 and Kidney Disease: A Clinical Perspective. Current Vascular Pharmacology, 2022, 20, 321-325.	0.8	2
9	Prognostic significance of risk factors and biomarkers in patients hospitalized for cardiorenal syndromes: A pilot study. Current Medicinal Chemistry, 2022, 29, .	1.2	0
10	Salt sensitivity and hypertension. Journal of Human Hypertension, 2021, 35, 184-192.	1.0	51
11	Joint ESH Excellence Centers™ National Meeting on Renal Sympathetic Denervation: a Greek Experts™ Survey. Hellenic Journal of Cardiology, 2021, 62, 355-358.	0.4	1
12	Dyslipidemia in Chronic Kidney Disease: Contemporary Concepts and Future Therapeutic Perspectives. American Journal of Nephrology, 2021, 52, 693-701.	1.4	18
13	Should we need more sensitive early diagnostic markers in children with congenital solitary functioning kidneys?. Journal of Clinical Hypertension, 2021, 23, 253-256.	1.0	0
14	Narrative review of recent studies on the role of vitamin D in the prevention of cardiac and renal risk and additional considerations for COVID-19 vulnerability. Current Vascular Pharmacology, 2021, 19, .	0.8	1
15	Metformin-associated lactic acidosis and acute kidney injury in the era of COVID-19. Frontiers in Bioscience - Scholar, 2021, 13, 202.	0.8	4
16	Serum vitamin D in obese and overweight subjects according to estimated glomerular filtration rate. Hormones, 2018, 17, 237-246.	0.9	2
17	Uric acid and incident chronic kidney disease in dyslipidemic individuals. Current Medical Research and Opinion, 2018, 34, 1193-1199.	0.9	25
18	Arterial damage and cognitive decline in chronic kidney disease patients. Journal of Clinical Hypertension, 2018, 20, 1276-1284.	1.0	15

#	ARTICLE	IF	CITATIONS
19	Treatment of Hypertension in Chronic Kidney Disease. <i>Current Hypertension Reports</i> , 2018, 20, 64.	1.5	34
20	Anticoagulant-related nephropathy: a case report and review of the literature of an increasingly recognized entity. <i>International Urology and Nephrology</i> , 2017, 49, 1401-1407.	0.6	28
21	Klotho, the Holy Grail of the kidney: from salt sensitivity to chronic kidney disease. <i>International Urology and Nephrology</i> , 2016, 48, 1657-1666.	0.6	15
22	Hyperphosphatemia and phosphate binders: effectiveness and safety. <i>Current Medical Research and Opinion</i> , 2014, 30, 109-112.	0.9	9
23	Effects of Nebivolol on Aortic Compliance in Patients With Diabetes and Maximal Renin Angiotensin System Blockade: The <sc>EFFORT</sc> Study. <i>Journal of Clinical Hypertension</i> , 2013, 15, 473-479.	1.0	15
24	Pros and Cons of Aggressive Blood Pressure Lowering in Patients with Type 2 Diabetes. <i>Current Vascular Pharmacology</i> , 2012, 10, 156-161.	0.8	16
25	The role of obesity in kidney disease: recent findings and potential mechanisms. <i>International Urology and Nephrology</i> , 2011, 43, 771-784.	0.6	55
26	The Role of Statins in Chronic Kidney Disease. <i>American Journal of Nephrology</i> , 2011, 34, 195-202.	1.4	37
27	Prehypertension: is it relevant for nephrologists?. <i>Kidney International</i> , 2010, 77, 194-200.	2.6	40
28	Serum Creatinine vs. Albuminuria as Biomarkers for the Estimation of Cardiovascular Risk. <i>Current Vascular Pharmacology</i> , 2010, 8, 604-611.	0.8	14
29	Are Renin-Angiotensin-Aldosterone System Blockers Distinguishable Based on Cardiovascular and Renal Outcomes in Nephropathy?. <i>Postgraduate Medicine</i> , 2009, 121, 77-88.	0.9	6
30	Predictors of Hyperkalemia Risk following Hypertension Control with Aldosterone Blockade. <i>American Journal of Nephrology</i> , 2009, 30, 418-424.	1.4	146
31	Pathogenesis and Treatment of Microalbuminuria in Patients With Diabetes: The Road Ahead. <i>Journal of Clinical Hypertension</i> , 2009, 11, 636-643.	1.0	30
32	Hypertension in Early-Stage Kidney Disease: An Update From the Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2009, 53, S22-S31.	2.1	30
33	The current state of RAAS blockade in the treatment of hypertension and proteinuria. <i>Current Cardiology Reports</i> , 2009, 11, 436-442.	1.3	14
34	Management of hypertension in patients with diabetes: the place of angiotensinâ€”receptor blockers. <i>Diabetes, Obesity and Metabolism</i> , 2009, 11, 757-769.	2.2	19
35	Should proteinuria reduction be the criterion for antihypertensive drug selection for patients with kidney disease?. <i>Current Opinion in Nephrology and Hypertension</i> , 2009, 18, 386-391.	1.0	22
36	Effects of angiotensin II receptor blockers on diabetic nephropathy. <i>Journal of Hypertension</i> , 2009, 27, S15-S21.	0.3	25

#	ARTICLE	IF	CITATIONS
37	Should nephrologists use beta-blockers? A perspective. <i>Nephrology Dialysis Transplantation</i> , 2008, 24, 701-702.	0.4	15
38	Disturbances of Phosphate Metabolism: Another Feature of Metabolic Syndrome. <i>American Journal of Kidney Diseases</i> , 2005, 45, 851-858.	2.1	61
39	Hypomagnesemia in Alcoholic Patients. <i>Alcoholism: Clinical and Experimental Research</i> , 1998, 22, 134-134.	1.4	22